Search Within

William Thomas Johnson

  1. "Sloan Kettering Institute Postdocs"
Formats
  1. Meeting Abstract (18)
  2. Journal Article (4)
  3. Research Letter (3)
Groups
  1. Center for Hematologic Malignancies (25)
  2. Department of Medicine (25)
  3. Hematologic Malignancies, Division of (25)
  4. Lymphoma (25)
  5. Sloan Kettering Institute Postdocs (25)
  6. Population Sciences Research Program (24)

More Groups

People
  1. Steven Horwitz (24)
  2. Alison Moskowitz (23)
  3. Anita Kumar (19)
  4. Ariela Noy (19)
  5. Gilles Salles (19)
  6. Lorenzo Falchi (19)

More People

Years
  1. 2025 (3)
  2. 2024 (6)
  3. 2023 (12)
  4. 2022 (1)
  5. 2021 (3)
Publications
  1. Blood (16)
  2. Haematologica (2)
  3. Hematological Oncology (2)
  4. Journal of Clinical Oncology (2)
  5. Blood Advances (1)
  6. Blood Cancer Journal (1)

More Publications

Publishers
  1. American Society of Hematology (17)
  2. Wiley Blackwell (3)
  3. American Society of Clinical Oncology (2)
  4. Ferrata Storti Foundation (2)
  5. Nature Publishing Group (1)

Results (25)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Impact of choice of platinum-based salvage therapy on CNS relapse in patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Buege, M. J.; Dao, P.; Dematteo, R. G.; LeVoir, A.; Pak, T.; Batlevi, C. L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save